C6orf170 Inhibitors
Chemical inhibitors of C6orf170 can disrupt various signaling pathways that are essential for its function. Wortmannin and LY294002, as PI3K inhibitors, obstruct the phosphatidylinositol 3-kinase pathway, which is a crucial cellular signaling route. This action can prevent downstream phosphorylation events required for C6orf170 activation. Rapamycin targets mTOR, another key player in the same pathway, leading to reduced activity of proteins regulated by mTOR signaling, which can include C6orf170. The effect of these inhibitors is a decrease in C6orf170 function due to the disruption of its signaling environment.
Further, PD98059 and U0126 are specific to the MEK1/2 enzymes within the MAPK/ERK pathway. By inhibiting these enzymes, they can decrease the level of ERK activation, which can in turn lead to reduced phosphorylation and activation of proteins downstream, potentially including C6orf170. In a similar vein, SB203580 and SP600125 work within the MAPK signaling pathway but target different kinases. SB203580 specifically inhibits p38 MAP kinase, while SP600125 inhibits JNK. Both actions can lead to a decrease in the activation of proteins involved in the corresponding pathways, thereby reducing C6orf170 activity. PP2, Dasatinib, and Imatinib are inhibitors of various tyrosine kinases. PP2 is specific to the Src family, Dasatinib broadly targets Src family kinases among others, and Imatinib targets bcr-abl tyrosine kinase and c-kit. By inhibiting these kinases, the signaling pathways and their proteins, which are crucial to the function of C6orf170, can be disrupted. Lastly, Sunitinib and Erlotinib inhibit receptor tyrosine kinases, with Sunitinib affecting PDGFR and VEGFR, and Erlotinib specifically inhibiting EGFR tyrosine kinase. The inhibition of these receptors leads to decreased signaling through their respective pathways, which can result in a reduction in C6orf170 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), which indirectly leads to functional inhibition of C6orf170 by disrupting the PI3K/AKT signaling pathway that is crucial for many cellular processes. Inhibition of this pathway can prevent the phosphorylation of proteins downstream of PI3K, potentially including C6orf170. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that hampers the PI3K/AKT pathway, similarly to Wortmannin, and can result in the functional inhibition of C6orf170 by blocking the phosphorylation cascade that might be necessary for C6orf170's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a downstream target of the PI3K/AKT pathway, which can lead to reduced activity of proteins regulated by this pathway, including C6orf170, due to decreased protein synthesis and cell growth processes that are dependent on mTOR signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK1/2, which blocks the MAPK/ERK pathway. This can result in lower activation of ERK and the downstream phosphorylation cascade, which may include C6orf170, hence functionally inhibiting C6orf170 by preventing its necessary phosphorylation for activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also specifically inhibits MEK1/2 in the MAPK/ERK pathway, leading to a decrease in ERK activation. With ERK activity reduced, proteins that are phosphorylated as a result of this pathway's activation, possibly including C6orf170, would be functionally inhibited. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, part of the MAPK pathway. This inhibition can decrease the activation of proteins involved in the cellular responses to stress, including C6orf170, resulting in its functional inhibition by preventing the phosphorylation that would be necessary for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, another kinase in the MAPK signaling pathway. Inhibition of JNK can lead to decreased activation of target proteins, including C6orf170, thereby functionally inhibiting it by blocking necessary phosphorylation events. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. By inhibiting these kinases, the phosphorylation and activation of associated signaling pathways and their proteins, potentially including C6orf170, would be functionally inhibited. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that can inhibit Src family kinases. Its inhibition of these kinases can lead to the functional inhibition of C6orf170 by reducing the activation of pathways necessary for the phosphorylation of C6orf170. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits bcr-abl tyrosine kinase and c-kit, potentially impacting the signaling pathways in which C6orf170 operates. This inhibition can functionally inhibit C6orf170 by reducing the phosphorylation and signaling events that C6orf170 would normally be involved in. | ||||||